Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Robohogs who wrote (17060)	6/13/2005 10:49:50 AM
From: rkrw	Respond to of 52153

I committed a nice chunk of my portfolio's to them as well. Reduced portfolio risk, yet strong returns, was too good to pass up. exel one is interesting. Certainly a lot more risk to Symphony, i.e. concerta was in one of the Alza vehicles, not novel anticaner compounds. I do think if these 3 cpds pass their phase IIa hurdles, gsk will opt in, so in a sense exel may be passing off future gsk milestones to Symphony. Given intense competition in the multi target cancer kinase space, I think full steam ahead at whatever short term cost is their best option. The risk of falling behind would be costlier.